Loading...
01/10 16:41
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
GeneDx shows strong financial performance with raised revenue and margin guidance and profitability expectations. NICU and pediatrics markets offer significant growth opportunities. While ASPs may decrease, the company is expanding its sales force and partnerships. Despite some uncertainties in short-term revenue from newborn screening, the overall outlook is bolstered by strategic investments and international expansion plans. The Q&A session reinforces positive sentiment with growth in core markets and proactive strategies, leading to an expected positive stock price movement.
Revenue for Q3 2025 $116.7 million, a 52% increase year-over-year. This growth was driven by a 66% increase in revenue from exome and genome testing, which totaled $98.9 million.
Exome and Genome Tests Volume 25,702 tests in Q3 2025, showing an acceleration in growth from 24% year-over-year in Q1 to 33% in Q3. This growth is attributed to increased ordering patterns and expansion into new markets.
Average Reimbursement Rate for Exome and Genome Tests Over $3,500 per test in Q3 2025, up from $3,100 a year ago. The increase is due to improved reimbursement and Medicaid coverage expansion.
Adjusted Gross Margin 74% in Q3 2025, driven by favorable mix shift, improved reimbursement, and lower costs of goods sold (COGS).
Adjusted Total Operating Expenses $71 million in Q3 2025, representing 61% of revenue. The increase is due to strategic investments in sales, marketing, R&D, and international market development.
Adjusted Net Income $14.7 million in Q3 2025, with an adjusted basic EPS of $0.51. This reflects strong demand and operational efficiency.
Cash and Cash Equivalents $156 million as of September 30, 2025. This includes $9 million in free cash flow generated during the quarter.
ExomeDx and GenomeDx tests: Received FDA breakthrough device designation, validating their industry-leading technology for transforming lives and shaping the future of health.
GeneDx Infinity: Largest rare disease data set used to generate deep genomic insights for fast and reliable diagnoses, fueling the precision medicine revolution.
Ultra-rapid genome testing: Proves its value for critically ill infants, with potential to scale testing in NICUs.
Pediatricians and NICU market: Expanding into general pediatricians and underpenetrated NICU markets, with plans to double the sales force and integrate into more hospitals.
International markets: Developing markets outside the U.S. with the Fabric genomics platform and local teams.
Revenue growth: Third quarter 2025 revenues reached $116.7 million, a 52% year-over-year increase, with exome and genome revenues up 66%.
Cost optimization: Leveraging automation and AI to reduce costs and improve gross margins, which reached 74% in Q3 2025.
Medicaid coverage expansion: Medi-Cal, the largest state Medicaid program, will begin covering whole genome testing, marking the 36th state to do so.
New executive hires: Appointed Lisa Gurry as Chief Business Officer and Dr. Mimi Lee as Chief Precision Medicine Officer to enhance data diagnostics and partnerships.
Shift to proactive care: Focusing on genomic newborn screening and adult conditions to transition from reactive to proactive personalized care.
Regulatory Hurdles: The company acknowledges that forward-looking statements inherently involve risks and uncertainties, which could cause actual results to materially differ from projections. This includes potential regulatory challenges in expanding coverage and adoption of genetic testing.
Market Penetration Challenges: The company is expanding into new markets, such as general pediatricians and international regions, which may initially have lower reimbursement rates and require significant investment in sales force and education. Adoption in these markets may take 18 to 24 months, posing a risk to short-term revenue growth.
Economic Uncertainties: Investments in new markets and customer experience innovations are expected to impact near-term operating margins. Economic conditions could affect the company's ability to sustain these investments.
Supply Chain and Operational Risks: The company relies on advanced genomic technologies and AI tools, which may face supply chain disruptions or technical challenges, potentially impacting production and service delivery.
Strategic Execution Risks: The company is making deliberate investments in new markets, technologies, and customer experience. Failure to achieve expected ROI or delays in execution could impact long-term growth and profitability.
Competitive Pressures: The company highlights its competitive moat through its GeneDx Infinity data set but acknowledges the need to maintain this advantage against competitors who may develop similar capabilities.
2025 Revenue Guidance: GeneDx has raised its 2025 revenue guidance to $425 million to $428 million, reflecting strong momentum and growth.
Exome and Genome Revenue Growth: The company expects exome and genome revenue to grow between 53% and 55% for the full year 2025, translating to $358 million to $361 million. Excluding a discrete benefit from 2024, the growth rate is projected at 57% to 60%.
Exome and Genome Volume Growth: GeneDx reaffirms its expectation of at least 30% exome and genome volume growth for 2025, with a fourth-quarter exit rate of at least 34%.
Adjusted Gross Margin: The company has raised its full-year 2025 adjusted gross margin guidance to between 70% and 71%.
NICU Market Penetration: GeneDx plans to significantly scale testing in Level 3 and Level 4 NICUs over time, with 8 Epic Aura integrations live and at least 12 expected by year-end.
Pediatric Market Expansion: The company is building out its commercial team to target general pediatricians, expecting adoption to take 18 to 24 months from the June 2025 update.
Newborn Screening Initiatives: GeneDx is advancing genomic newborn screening programs, including the GUARDIAN study and partnerships with the NIH Beacon program and Sunshine Genetics Network, aiming for broad adoption to shift from reactive to proactive care.
International Market Development: The company is expanding its presence in key international markets, leveraging the Fabric genomics platform to serve global markets at scale.
AI and Automation in Genomics: GeneDx is investing in AI and automation to optimize production, reduce costs, and improve turnaround times, with the potential to make ultra-rapid genome testing the standard of care.
The selected topic was not discussed during the call.
GeneDx shows strong financial performance with raised revenue and margin guidance and profitability expectations. NICU and pediatrics markets offer significant growth opportunities. While ASPs may decrease, the company is expanding its sales force and partnerships. Despite some uncertainties in short-term revenue from newborn screening, the overall outlook is bolstered by strategic investments and international expansion plans. The Q&A session reinforces positive sentiment with growth in core markets and proactive strategies, leading to an expected positive stock price movement.
The earnings call reflects strong financial performance, with record high adjusted gross margins and consistent profitability. Revenue guidance has been raised, and significant volume growth is expected. The Q&A section reveals confidence in ASP durability and strategic investments in the pediatric market. Although management was vague on certain specifics, the overall sentiment is positive, driven by successful integration of acquisitions, improved payment rates, and expanded Medicaid coverage. The absence of a market cap suggests a cautious 'Positive' rating due to potential volatility.
The earnings call highlighted strong financial performance with a 62% revenue increase and improved margins. Despite competitive and regulatory risks, the company has shown profitability and a robust balance sheet. The Q&A revealed confidence in managing expenses and future growth, though some answers were vague. The issuance of shares and integration risks pose challenges, but overall, the positive financial metrics and optimistic guidance outweigh these concerns, suggesting a positive market reaction.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
